MSTN: A Protein Implicated in Many Diseases (G2660)

Target Name: MSTN

NCBI ID: G2660

MSTN

MSTN: A Protein Implicated in Many Diseases

MSTN (Mesothelin-associated protein N) is a protein that is expressed in various tissues throughout the body, including the skin, lungs, heart, and brain. It is a member of the mesothelin family, which is known for its role in cell- cell adhesion and tissue signaling. MSTN has also been shown to play a role in the development and progression of various diseases, including cancer. As a result, MSTN has become a focus of interest for researchers as a potential drug target or biomarker.

The mesothelin family of proteins is composed of four subclasses: Type I (Mesothelin-1), Type II (Mesothelin-2), Type III (Mesothelin-3), and Type IV (Mesothelin-4). All of these subclasses share a conserved extracellular matrix (ECM) domain and a unique N-terminus. The ECM domain is composed of a repeated sequence of amino acids that includes a variety of domains, such as a transmembrane region, a cytoplasmic domain, and a lysine-rich region. The N-terminus of each subclass protein ends with a unique amino acid that is involved in cell-cell adhesion and/or tissue signaling.

MSTN is a member of the Type II subclass of mesothelin proteins. It is characterized by a single N-terminus that is composed of the amino acids Asp-21, Asn-22, Glu-23, and Lys-24. MSTN has a calculated molecular weight of 61 kDa and a calculated pI of 6.3.

MSTN has been shown to play a role in various physiological processes in the body, including cell adhesion, migration, and invasion. For example, MSTN has been shown to be involved in the regulation of cell adhesion in various tissues, including the skin and the placenta. It has also been shown to play a role in the regulation of cell migration and invasion, including the regulation of the migratory properties of cancer cells.

In addition to its role in cell biology, MSTN has also been shown to be involved in the development and progression of various diseases. For example, MSTN has been shown to be involved in the development of cancer, including breast and ovarian cancers. It has has also been shown to be involved in the progression of other diseases, including heart disease and neurodegenerative diseases.

As a result of its involvement in various diseases, MSTN has become a focus of interest for researchers as a potential drug target or biomarker. Studies have shown that MSTN can be targeted by small molecules, including inhibitors of its signaling pathway. In addition, there is growing interest in using MSTN as a diagnostic biomarker for various diseases, including cancer.

One of the challenges in studying MSTN is its complex biochemical and cellular interactions. While much has been learned about its role in various physiological processes, much remains to be understood about its role in diseases. Additionally, the lack of well-studied structures and functions of MSTN make it difficult to predict its potential therapeutic effects.

Despite these challenges, research into MSTN is ongoing, and there is growing interest in its potential as a drug target or biomarker. As research continues, it is likely that the role of MSTN in various diseases will become better understood, and its potential as a therapeutic agent will be discovered.

In conclusion, MSTN is a protein that has been shown to play a role in various physiological processes in the body, including cell adhesion, migration, and invasion. Its involvement in the development and progression of various diseases has made it a focus of interest for researchers as a potential drug target or biomarker. Further research is needed to fully understand its role in diseases and its potential as a therapeutic agent.

Protein Name: Myostatin

Functions: Acts specifically as a negative regulator of skeletal muscle growth

The "MSTN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MSTN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets